177
Participants
Start Date
January 5, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2026
HS-20089 (Phase Ia：Dose escalation )
Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
HS-20089 (Phase Ib: Dose expansion)
IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
RECRUITING
Fudan University Cancer Hospital, Shanghai
Shanghai Hansoh Biomedical Co., Ltd
INDUSTRY